View in EDS HTML Full Text PDF Full Text

Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab.

Saved in:
Bibliographic Details
Title: Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab.
Authors: Campani, Claudia1,2,3 (AUTHOR), Bamba‐Funck, Jessica4,5 (AUTHOR), Campion, Bertille6 (AUTHOR), Sidali, Sabrina1,7 (AUTHOR), Blaise, Lorraine1,8,9 (AUTHOR), Ganne‐Carrié, Nathalie1,8,9 (AUTHOR), Demory, Alix8 (AUTHOR), Sutter, Olivier10 (AUTHOR), Larrey, Edouard6 (AUTHOR), Evain, Manon6 (AUTHOR), Ghannouchi, Haroun10 (AUTHOR), Wagner, Mathilde11 (AUTHOR), Marra, Fabio3 (AUTHOR), Sutton, Angela4,5 (AUTHOR), Allaire, Manon6 (AUTHOR), Nault, Jean‐Charles1,2,8,9 (AUTHOR) naultjc@gmail.com
Source: Liver International. Mar2023, Vol. 43 Issue 3, p708-717. 10p. 4 Charts, 3 Graphs.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14783223
DOI:10.1111/liv.15487